Circulation最新文献

{"title":"Pulmonary Hypertension: From Therapeutic Nihilism to Multiple Therapeutic Interventions.","authors":"Vallerie V McLaughlin, Marc Humbert","doi":"10.1161/CIRCULATIONAHA.124.070104","DOIUrl":"https://doi.org/10.1161/CIRCULATIONAHA.124.070104","url":null,"abstract":"","PeriodicalId":10331,"journal":{"name":"Circulation","volume":"150 21","pages":"1653-1655"},"PeriodicalIF":35.5,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142667446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Precision Medicine for Cardiovascular Prevention and Population Health: A Bridge Too Far?","authors":"Fernando R Giugni, Jarett D Berry, Amit Khera, Amil M Shah, James A de Lemos","doi":"10.1161/CIRCULATIONAHA.124.070081","DOIUrl":"https://doi.org/10.1161/CIRCULATIONAHA.124.070081","url":null,"abstract":"<p><p>Precision medicine aims to provide personalized clinical care guided by tools that reflect underlying pathophysiology. The need for such an approach has never been greater in cardiovascular medicine, given the large number of guideline-directed medical therapies available. However, progress has been modest to date with few precision tools available for clinicians. Arguably, cardiovascular prevention and population health are poised for innovation to guide evaluation and management, as these areas are already informed by risk-assessment, but limited by the use of crude assessment tools with marginal performance. Risk assessment in prevention and population health may be improved with the use of genetics, circulating biomarkers, and imaging, leading to outcome-specific risk-prediction and enhanced phenotyping. Personalized management matching therapy to risk profile can be then implemented for either individuals or groups, improving cost-effectiveness and risk-benefit. Here, we explore this precision-like approach, including available tools, potential applications, and future perspectives for cardiovascular prevention and population health management.</p>","PeriodicalId":10331,"journal":{"name":"Circulation","volume":"150 21","pages":"1720-1731"},"PeriodicalIF":35.5,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142667445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Screening for Cardiac Involvement in Carriers of Pathogenic <i>TTR</i> Variants: Proposal for an Approach Based on High-Sensitivity Troponin.","authors":"Alberto Aimo, Chiara Sanguinetti, Maria Franzini","doi":"10.1161/CIRCULATIONAHA.124.071253","DOIUrl":"https://doi.org/10.1161/CIRCULATIONAHA.124.071253","url":null,"abstract":"","PeriodicalId":10331,"journal":{"name":"Circulation","volume":"150 21","pages":"1656-1658"},"PeriodicalIF":35.5,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142667447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: 2024 AHA/ACC/ACS/ASNC/HRS/SCA/SCCT/SCMR/SVM Guideline for Perioperative Cardiovascular Management for Noncardiac Surgery: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.","authors":"","doi":"10.1161/CIR.0000000000001298","DOIUrl":"https://doi.org/10.1161/CIR.0000000000001298","url":null,"abstract":"","PeriodicalId":10331,"journal":{"name":"Circulation","volume":"150 21","pages":"e466"},"PeriodicalIF":35.5,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142667441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter by Lucijanic and Krecak Regarding Article, \"Clonal Hematopoiesis of Indeterminate Potential With Loss of <i>Tet2</i> Enhances Risk for Atrial Fibrillation Through <i>Nlrp3</i> Inflammasome Activation\".","authors":"Marko Lucijanic, Ivan Krecak","doi":"10.1161/CIRCULATIONAHA.124.069352","DOIUrl":"https://doi.org/10.1161/CIRCULATIONAHA.124.069352","url":null,"abstract":"","PeriodicalId":10331,"journal":{"name":"Circulation","volume":"150 21","pages":"e447-e448"},"PeriodicalIF":35.5,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142667443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Atrial Arrhythmias After PFO Device Closure: Common, Clinically Important, and Preventable?","authors":"Jonathan M Tobis, John D Carroll","doi":"10.1161/CIRCULATIONAHA.124.071851","DOIUrl":"https://doi.org/10.1161/CIRCULATIONAHA.124.071851","url":null,"abstract":"","PeriodicalId":10331,"journal":{"name":"Circulation","volume":"150 21","pages":"1669-1670"},"PeriodicalIF":35.5,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142667429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Complex Anterior Mediastinal Mass in a Young Adult.","authors":"Giselle Alexandra Suero-Abreu, Lily Sung, Anushri Parakh, Brian Ghoshhajra, Tomas G Neilan, Doreen DeFaria Yeh, Yin P Hung, Danielle B Cameron, Jordan P Bloom","doi":"10.1161/CIRCULATIONAHA.123.067585","DOIUrl":"10.1161/CIRCULATIONAHA.123.067585","url":null,"abstract":"","PeriodicalId":10331,"journal":{"name":"Circulation","volume":" ","pages":"1737-1740"},"PeriodicalIF":35.5,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89717194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low-Density Lipoprotein Cholesterol Level Distributions Across Different Ages: Implications for Screening Children for Severe and Familial Hypercholesterolemia.","authors":"Junxiu Liu, Brandon K Bellows, David R Jacobs, Jessica G Woo, Elaine M Urbina, Pallavi P Balte, Elizabeth C Oelsner, Dhruv S Kazi, David Siscovick, Norrina B Allen, Jamal S Rana, John T Wilkins, Michael E Hall, Lydia A Bazzano, Trudy L Burns, Stephen R Daniels, Terence Dwyer, Markus Juonala, Olli T Raitakari, Alan R Sinaiko, Julia Steinberger, Alison J Venn, Noora Kartiosuo, Terho Lehtimäki, Costan G Magnussen, Jorma S A Viikari, Sarah D de Ferranti, Andrew E Moran, Yiyi Zhang","doi":"10.1161/CIRCULATIONAHA.124.069792","DOIUrl":"https://doi.org/10.1161/CIRCULATIONAHA.124.069792","url":null,"abstract":"","PeriodicalId":10331,"journal":{"name":"Circulation","volume":"150 21","pages":"1741-1744"},"PeriodicalIF":35.5,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142667444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Highlights From the <i>Circulation</i> Family of Journals.","authors":"","doi":"10.1161/CIRCULATIONAHA.124.072367","DOIUrl":"https://doi.org/10.1161/CIRCULATIONAHA.124.072367","url":null,"abstract":"","PeriodicalId":10331,"journal":{"name":"Circulation","volume":"150 21","pages":"1732-1736"},"PeriodicalIF":35.5,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142667442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial).","authors":"Yugo Yamashita, Takeshi Morimoto, Nao Muraoka, Wataru Shioyama, Ryuki Chatani, Tatsuhiro Shibata, Yuji Nishimoto, Yoshito Ogihara, Kosuke Doi, Maki Oi, Taro Shiga, Daisuke Sueta, Kitae Kim, Yasuhiro Tanabe, Norimichi Koitabashi, Takuma Takada, Satoshi Ikeda, Hitoshi Nakagawa, Kengo Tsukahara, Masaaki Shoji, Jiro Sakamoto, Shinji Hisatake, Yutaka Ogino, Masashi Fujita, Naohiko Nakanishi, Tomohiro Dohke, Seiichi Hiramori, Ryuzo Nawada, Kazuhisa Kaneda, Koh Ono, Takeshi Kimura","doi":"10.1161/CIRCULATIONAHA.124.072758","DOIUrl":"10.1161/CIRCULATIONAHA.124.072758","url":null,"abstract":"<p><strong>Background: </strong>The optimal duration of anticoagulation therapy for patients with cancer and acute low-risk pulmonary embolism (PE) is clinically relevant, but evidence is lacking. Prolonged anticoagulation therapy could have a potential benefit for prevention of thrombotic events; however, it could also increase the risk of bleeding.</p><p><strong>Methods: </strong>In a multicenter, open-label, adjudicator-blinded, randomized clinical trial at 32 institutions in Japan, we randomly assigned patients with cancer and acute low-risk PE of the simplified version of the Pulmonary Embolism Severity Index score of 1, in a 1:1 ratio, to receive either an 18-month or a 6-month rivaroxaban treatment. The primary end point was recurrent venous thromboembolism (VTE) at 18 months. The major secondary end point was major bleeding at 18 months according to the criteria of the International Society on Thrombosis and Hemostasis. The primary hypothesis was that an 18-month treatment was superior to a 6-month treatment in terms of the primary end point.</p><p><strong>Results: </strong>From February 2021 to March 2023, 179 patients were randomized, and after the exclusion of one patient who withdrew consent, 178 were included in the intention-to-treat population: 89 patients in the 18-month rivaroxaban group and 89 in the 6-month rivaroxaban group. The mean age was 65.7 years; 47% of the patients were men, and 12% had symptoms of PE at baseline. The primary end point of recurrent VTE occurred in 5 of the 89 patients (5.6%) in the 18-month rivaroxaban group and in 17 of the 89 (19.1%) in the 6-month rivaroxaban group (odds ratio, 0.25 [95% CI, 0.09-0.72]; <i>P</i>=0.01). Among 22 recurrent VTE, 5 patients presented with a symptomatic recurrent VTE; recurrent PE occurred in 11 patients, including 2 with main and 4 with lobar PEs; and recurrent deep vein thrombosis was seen in 11 patients, including 3 with proximal deep vein thromboses. The major secondary end point of major bleeding occurred in 7 of the 89 patients (7.8 %) in the 18-month rivaroxaban group and in 5 of the 89 patients (5.6%) in the 6-month rivaroxaban group (odds ratio, 1.43 [95% CI, 0.44-4.70]; <i>P</i>=0.55).</p><p><strong>Conclusions: </strong>In patients with cancer and acute low-risk PE of the simplified version of the Pulmonary Embolism Severity Index score of 1, the 18-month rivaroxaban treatment was superior to the 6-month rivaroxaban treatment with respect to recurrent VTE events.</p>","PeriodicalId":10331,"journal":{"name":"Circulation","volume":" ","pages":""},"PeriodicalIF":35.5,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142647068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}